Table 1 Descriptive statistics of the cohort study
Characteristic | All patients |
|---|---|
N | 3523 |
Age at cohort entry, median [IQR] | 85 [78–89] |
Female sex, n (%) | 1339 (38.0) |
Rx-risk comorbidity scorea,b, median [IQR] | 5 [3–6] |
Hypertensiona n (%) | 1598 (45.4) |
Congestive heart failurea n (%) | 809 (23.0) |
Diabetesa n (%) | 442 (12.5) |
Co-morbid osteoarthritis, n (%) | 2453 (69.6) |
Controlled release paracetamol, n (%) | 2357 (66.9) |
Hospitalization with osteoarthritis, n (%) | 410 (11.6) |
High baseline COPD severityc, n (%) | 1364 (38.7) |
Prior oral cortisone usea, n (%) | 1062 (30.1) |
One or more prior COPD hospitalizationsa, n (%) | 562 (16.0) |
Any statin use during follow-up, n (%) | 1883 (53.4) |
Hospitalization for respiratory infection at end of follow-up, n (%) | 189 (5.4) |
Days exposed, median [IQR] | 99 [33–283] |
Proportion of time exposed during follow up, median [IQR] | 0.254 [0.097–0.565] |
Chronic usersd, n (%) | 2245 (63.7%) |
Follow up (years), median [IQR] | 1.98 [0.72–3.43] |
COPD hospitalization during follow up, n (%) | 619 (17.6%) |